1. Travis W, Brambilla E, Burke A, Marx A, Nicholson A. WHO classification of tumors of the lung, pleura, thymus and heart. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2015.
2. Anon. Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med. 1997;156:320–32.
3. Colby TV, Koss M, Travis WD. Tumors of the lower respiratory tract. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1995.
4. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48:5738–41.
5. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with nonsmall cell lung cancer: a meta-analysis. Clin Cancer Res. 2000;6:4055–63.